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ABSTRACT  
The disordered Tubulin Polymerization Promoting Protein (TPPP/p25), a prototype of 
neomorphic moonlighting proteins, displays physiological and pathological functions 
by interacting with distinct partners. Here the role of the disordered N- and C- termini 
straddling a middle flexible segment in the distinct functions of TPPP/p25 was 
established, and the binding motives responsible for its heteroassociations with 
tubulin and -synuclein, its physiological and pathological interacting partner, 
respectively, were identified. We showed that the truncation of the disordered termini 
altered the folding state of the middle segment and has functional consequences 
concerning its physiological function. Double truncation diminished its binding to 
tubulin/microtubules, consequently the tubulin polymerization/microtubule bundling 
activities of TPPP/p25 were lost highlighting the role of the disordered termini in its 
physiological function. In contrast, interaction of TPPP/p25 with -synuclein was not 
affected by the truncations and its -synuclein aggregation promoting activity was 
preserved, showing that the -synuclein binding motif is localized within the middle 
segment. The distinct tubulin and -synuclein binding motives of TPPP/p25 were also 
demonstrated at the cellular level: the double truncated TPPP/p25 did not align along 
the microtubules in contrast to the full length form, while it induced -synuclein 
aggregation. The localization of the binding motives on TPPP/p25 were established 
by specific ELISA experiments performed with designed and synthesized peptides: 
motives at the 178-187 and 147-156 segments are involved in the binding of tubulin 
and -synuclein, respectively. The dissimilarity of these binding motives responsible 
for the neomorphic moonlighting feature of TPPP/p25 has significant innovative 
impact in anti-Parkinson drug research.  
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1. INTRODUCTION 
The recognition that there are proteins with more than one function was recognized 
two decades ago and this characteristic was termed first as gene sharing and later as 
moonlighting [1-3]. Moonlighting proteins perform multiple, independent functions 
that are not coded at gene level, do not stem from genetic alterations (gene fusion, 
splice variants or mutations), these functions are manifested at the protein level. The 
functions of these moonlighting proteins can vary as a consequence of changes in 
cellular localization, cell type, oligomeric state, concentrations of substrates, cofactors 
or products [3]. Moonlighting should also be distinguished from multifunctionality of 
proteins, in which a protein has multiple domains, each fulfilling a different function 
[2].  Recently a subclass of the moonlighting proteins has been defined as 
Neomorphic Moonlighting Proteins in which conformational changes and/or 
interactions with distinct partners other than at normal conditions impart a 
pathological function [4]. Therefore, in the case of these moonlighting proteins the 
physiological function could be converted into a pathological one [4-5]. 
Moonlighting is characteristic for many disordered proteins which do not have stable, 
well-defined 3D structures thus can adapt conformations upon binding to their 
partners [6-7]. Proteins with such features are rather common in living cells. They 
perform essential functions such as regulation of transcription and translation or 
cellular signal transduction [6, 8]. Besides that, disordered proteins also play crucial 
roles in the etiology of conformational diseases such as Parkinson’s (PD) and 
Alzheimer’s diseases [9-10]. 
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Tubulin Polymerization Promoting Protein (TPPP/p25) is an intrinsically disordered 
protein, its extended unstructured N- and C-terminal regions (45 and 44 aa) are 
straddling a middle flexible segment (130 aa) [11]. It is considered as a prototype of 
the neomorphic moonlighting proteins as under physiological and pathological 
conditions it performs multiple functions depending on its interacting partners. 
TPPP/p25 was isolated and identified as a brain-specific protein [12] and on the basis 
of its in vitro function and apparent molecular mass it was denoted TPPP/p25 [13]. 
Physiologically TPPP/p25 is expressed mainly in the oligodendrocytes [14] of brain 
and plays a crucial role in their differentiation process [15]. Its major physiological 
interacting partner is the tubulin/microtubule network and it modulates microtubule 
dynamics and organization via its microtubule bundling activity enhancing 
microtubule stability [13, 16-17]. In fact, TPPP/p25 also interacts with the tubulin 
deacetylase enzyme, HDAC6, and inhibits its deacetylase activity and thus plays a 
role in the control of the acetylation level of microtubules [17]. In addition, TPPP/p25 
binds GTP and catalyzes its hydrolysis in a Mg
2+
-dependent manner in vitro [11]. 
The non-physiological expression level of TPPP/p25 is coupled with distinct central 
nervous system diseases such as multiple sclerosis (altered expression in the brain and 
increased TPPP/p25 level in the cerebrospinal fluid of the patients) [18-19], 
oligodendrogliomas (lack of TPPP/p25 expression) [20] or conformational diseases 
(co-enrichment of TPPP/p25 and -synuclein in inclusion bodies) [21]. The 
development of the conformational diseases originates from the formation of aberrant 
protein-protein interactions leading to protein aggregation and pathological inclusion 
body formation. It has recently been reported that TPPP/p25 interacts with -
synuclein and -amyloid and promotes their aggregation in vitro [22-23]. The 
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involvement of TPPP/p25 in such pathological associations leads to the etiology of 
PD and Multiple System Atrophy as we demonstrated earlier [21]. 
In this paper the structural and functional roles of the disordered termini of TPPP/p25 
were characterized in its physiological and pathological functions, in addition, the 
tubulin and the -synuclein binding motives of TPPP/p25 involved within these 
functions were identified. 
2. MATERIALS AND METHODS 
2.1 Synthesis of the peptides 
The peptides BF180-183 were synthesized manually by Solid Phase Peptide Synthesis 
(SPPS), using Fmoc/tBu chemistry on 4-methylbenzhydrylamine resin. The 
biotinylated forms were made using biotinyl-6-amino-hexanoic acid (long chain 
biotin). In the case of BF183 and BF180 a Lys was built into the C-terminus of the 
peptides to conjugate the biotin derivative to its side chain (ε-amino group). The N-
terminus of the peptides was acetylated, while the C-terminus was in amide form. The 
peptides were cleaved from the resin with anhydrous HF in the presence of p-cresol at 
0 °C. The P1-P4 peptides were synthesized by automated SPPS (Syro2000; 
MultiSynTech GmbH, Germany), using Fmoc/tBu strategy on 4-
methylbenzhydrylamine resin with double-coupling protocol. A Cys was built into the 
N-terminus of the peptides. The N-terminus of the peptides was acetylated, while the 
C-terminus was in amide form. The peptides were cleaved from the resin with 
trifluoroacetic acid in the presence of scavengers (ethanedithiol, tioanizol, H2O, 
phenol). The crude products in each case were purified by reversed-phase 
chromatography and the purified compounds were characterized by analytical RP-
HPLC and mass spectrometry (PE-SCIEX API-2000 triple quadrupole instrument, 
Perkin-Elmer). 
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2.2 DNA manipulations  
Prokaryotic expression vectors containing inserts for human full length TPPP/p25 and 
N-terminal truncated TPPP/p25 by amino acid residues 3–43 (TPPP/p25 delta 3-43) 
were prepared and purified as described previously [17]. C-terminal truncated 
TPPP/p25 by residues 175-219 (TPPP/p25 delta 175-219) was amplified by 
polymerase chain reaction (PCR) using forward primer 5’- AGATACACATATG 
GCTGACAAGGCTAAGC-3’, and reverse primer 5’- GGTGCTCGAGGCCCG 
TGAACTTGGTGGTGTC-3’. The double truncated TPPP/p25 corresponding to 
amino acid residues 44–174 (TPPP/p25 delta 3-43/delta 175-219) was amplified by 
PCR using forward primer 5’- GAGATATACATATGGCTGCATCCCCTGAGCTC-
3’ and reverse primer 5’- GGTGCTCGAGGCCCGTGAACTTGGTGGTGTC -3’. 
After digestion with NdeI and XhoI restriction enzymes inserts were ligated into 
pET21c vector (Novagen). Eukaryotic expression vectors containing inserts for 
human full length TPPP/25 (pEGFP-TPPP/p25) were prepared as described 
previously [16]. The double truncated TPPP/p25 (pEGFP-TPPP/p25 delta 3-43/delta 
175-219) was amplified by PCR using the following primer pairs:  5’-GGAATTC 
TATGGCTGCATCCCCTGAG-3’; 5’-ATGGATCCCTAGCCCGTGAACTTGGT-3’ 
and pEGFP-TPPP/p25 as a template.  After digestion with EcoRI and BamHI 
restriction enzymes inserts were ligated into pEGFP-C1 vector (Clontech). Correct 
insertion of all these plasmids was verified by DNA sequencing.  
2.3 Recombinant TPPP/p25 protein purification 
Human recombinant TPPP/p25 forms possessing a His-tag were expressed in E. coli 
BL21 (DE3) cells and isolated on HIS-Select™ Cartridge (Sigma-Aldrich) as 
described previously [19, 21]. Protein concentrations were determined from the 
absorbance at 280 nm using an extinction coefficient of 10095 M
−1
 *cm
−1
, 10095 M
−1
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*cm
−1
, 5625 M
−1
 *cm
−1
 and 5625 M
−1
 *cm
−1
 for TPPP/p25, N-terminal truncated 
TPPP/p25, C-terminal truncated TPPP/p25 and double truncated TPPP/p25, 
respectively. 
2.4 Tubulin preparation  
Tubulin was prepared from bovine brain according to the method of Na and 
Timasheff [24].  
2.5 -synuclein purification 
Human recombinant -synuclein was prepared as described previously [25]. Protein 
concentration was determined from the absorbance at 280 nm using an extinction 
coefficient of 5960 M
−1
 *cm
−1
. 
2.6 Circular dichroism (CD) spectroscopy 
CD measurements were performed on Jasco J-720 spectropolarimeter at 20 nm/min 
scan rate, 8 s time constant and 0.5 nm step size in 10 mM phosphate buffer, pH 7.2 at 
room temperature. The path length was 0.1 cm. The protein concentrations were 4 μM 
for TPPP/p25 forms and 1 μM for tubulin. The reaction mixtures were incubated for 
10 minutes before recording the spectra. Scanning was repeated three times, and the 
spectra were averaged. Mean molar ellipticity per residue ( ) in degrees square 
centimeter per decimole was calculated according to the following equation:  = 
m/(10*n*c*l), where m is the measured ellipticity in millidegrees, n is the number 
of amino acid residues, c is the concentration in moles and l is the path length of the 
cell in centimetres.  
2.7 Fourier transformed infrared spectroscopy (FT-IR) 
FT-IR spectra of the different TPPP/p25 forms were recorded with a Bruker 
Equinox55 FT-IR spectrometer equipped with a liquid-nitrogen-cooled MCT detector. 
The proteins (1 mM) were dissolved in 12 mM phosphate buffer containing 110 mM 
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NaCl with D2O at pD 6.0. Spectra were obtained by co-adding 128 scans at a spectral 
resolution of 4 cm
-1
 in a BaF2 cell with a 50 m spacer. 
2.8 Limited proteolysis 
TPPP/p25 forms at 1 mg/ml were digested with 0.01 mg/ml chymotrypsin (Sigma-
Aldrich) in 50 mM tris(hydroxymethyl)aminomethane buffer pH 8.0 containing 10 
mM CaCl2 at room temperature. A control sample did not contain protease.  Aliquots 
were drawn from each sample at different time points. The digestion was terminated 
by 1 mM 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride. The samples were 
analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), 
separated on a Tricin-containing two-layer-gel and stained with Coomassie Brilliant 
Blue R-250 containing 2-mercaptoethanol and dithioerythritol (DTE). 
2.9 Fluorescence spectroscopy  
Thioflavin T fluorescence. TPPP/p25 proteins (10 M) without and with -synuclein 
(150 M) were incubated for 3-4 days at 37 °C in phosphate buffered saline (PBS) 
buffer.  Then a 10 l aliquot was added to 1 ml 10 M thioflavin T solution in 100 
mM glycine buffer, pH 8.55. The fluorescence spectra were measured on a 
FluoroMax-3 spectrofluorometer (Jobin Yvon Inc.), using thermostated quartz 
cuvettes of 1 cm optical path length at 37 °C. Data were processed using DataMax 
software. Scanning was repeated three times, and the spectra were averaged, the 
buffer spectrum was subtracted in each case. Spectra were recorded at an excitation 
wavelength ( ex) of 440 nm (slit width 4 nm), emission spectra were collected from 
450 to 600 nm (slit width 4 nm).  
1-anilino naphthalene-8-sulfonic acid (ANS) fluorescence. Fluorescence spectroscopy 
measurements were performed in 10 mM phosphate buffer, pH 7.2 using a 
Fluoromax-3 spectroﬂuorometer (Jobin Yvon Inc.) in a quartz cuvette of 1 cm optical 
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path length at 25 °C. Excitation wavelength was 380 nm, while the emission was 
monitored from 400 to 600 nm with 2 nm slits. The data of at least three parallel 
measurements were evaluated using DataMax software. 10 mM ANS (Sigma-Aldrich) 
stock solution was freshly prepared in distilled water. Concentrations of TPPP/p25 
forms and ANS were 2.5 and 50 μM, respectively. 
2.10 Enzyme-linked immunosorbent assay (ELISA)  
The plate was coated with 5 g/ml (100 l/well) TPPP/p25 forms in PBS overnight at 
4 °C. The wells were blocked with 1 mg/ml bovine serum albumin (BSA) in PBS for 
1 h at room temperature. Next, the plate was incubated with serial dilutions of -
synuclein for 1 h at room temperature in PBS. In the case of the competitive ELISA, 
the plate was incubated with 500 nM -synuclein preincubated without or with the 
biotinylated peptides (10 and 20 M). Then the plate was sequentially incubated with 
-synuclein antibody (1:5000, Sigma-Aldrich) and with the peroxidase conjugated 
secondary IgG (1:5000, Sigma-Aldrich). Both antibodies were in PBS buffer 
containing 1 mg/ml BSA, and incubated for 1 h at room temperature. Between each 
incubation step the wells were washed thrice with PBS containing 0.05% Tween 20 
for 10 min. The presence of antibodies was detected using o-phenylenediamine in the 
concentration of 3.7 mM with 0.03% H2O2 as substrate solution. The reaction was 
stopped after 10 min with 1 M H2SO4, and the absorbance was read at 490 nm with a 
Wallace Victor 2 multiplate reader (Perkin Elmer).  In the case of the biotinylated 
peptides, the plate was coated with 5 g/ml (100 l/well) streptavidin solution in PBS 
overnight at 4 °C, and the wells were blocked with 1 mg/ml BSA in PBS for 1 h at 
room temperature. Then the plate was incubated with 25 g/ml solution of the 
biotinylated peptides for 1 h at room temperature in PBS. Next, the plate was 
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incubated with serial dilutions of -synuclein, and the interaction was detected as 
described above. 
In the case of P1-P4 peptides, Sulfhydryl-BIND™ (Maleimide) Modified Surface 
plate (Corning Incorporated) was used according to the manufacturer’s instructions. 
Briefly, the plate was coated with 5 g/ml (100 l/well) peptide or TPPP/p25 solution 
in fresh PBS buffer containing 1 mM ethylenediamine tetraacetic acid pH 6.5 for 1 h 
at room temperature. The wells were blocked with 0.2% non-fat dry milk in PBS for 
30 min at room temperature. Next, the plate was incubated with serial dilutions of 
tubulin for 30 min at room temperature in PBS. Then the plate was sequentially 
incubated with tubulin antibody (1:5000, Sigma-Aldrich), and with the corresponding 
peroxidase conjugated secondary IgG (1:5000, Sigma-Aldrich). o-phenylenediamine 
was used as substrate solution as described above.  
2.11 Turbidity measurements 
The assembly of tubulin (7 M) was assessed in polymerization buffer (50 mM 2-(N-
morpholino)ethanesulfonic acid buffer pH 6.6 containing 100 mM KCl, 1 mM DTE, 1 
mM MgCl2 and 1 mM ethylene glycol tetraacetic acid) at 37 °C. The tubulin 
polymerization into microtubules was induced by the addition of 3 M of the different 
TPPP/p25 forms. In another set of experiments, the polymerization of 10 M tubulin 
into microtubules was induced by the addition of 20 M paclitaxel then subsequently 
3 M TPPP/p25 proteins were added to the solution.  The optical density was 
monitored at 350 nm by a Cary 100 spectrophotometer (Varian).  
2.12 Pelleting experiment 
 Tubulin (5 M) was incubated with the different TPPP/p25 forms (10 M) for 10 
min at 37 °C in polymerization buffer (50 mM 2-(N-morpholino)ethanesulfonic acid 
buffer pH 6.6 containing 100 mM KCl, 1 mM DTE, 1 mM MgCl2 and 1 mM ethylene 
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glycol tetraacetic acid). After centrifugation at 17000 g for 15 min at 37 °C, the pellet 
and the supernatant fractions were separated. The pellet fraction was washed and 
resuspended in buffer. Then the pellet and the supernatant fractions were analyzed by 
SDS-PAGE, separated on a Tricine-containing two-layer-gel and stained with 
Coomassie Brilliant Blue R-250 containing 2-mercaptoethanol and DTE.  
2.13 Cell Culture and Manipulation 
HeLa and CHO10 cells were grown and transfected as described previously [16-17]. 
For microscopic analysis cells were grown on 12 mm diameter coverslips and on 24-
well plates for immunoblotting. 5 µM MG132 (Sigma-Aldrich) was added for 4 
hours, where indicated. Uptake of TPPP/p25 forms and/or -synuclein was 
investigated by the addition of 2.5/10 g recombinant proteins into the medium 
freshly dissolved in PBS buffer with or without a short preincubation.  
2.14 Immunocytochemistry 
HeLa and CHO10 cells were fixed with ice-cold methanol for 10 minutes. After 
washes with PBS, samples were blocked for 30 minutes in PBS-0.1% Triton X-100 
containing 5% fetal calf serum. Subsequently, the cells were stained with a 
monoclonal antibody against -tubulin (Sigma-Aldrich), a monoclonal antibody 
against -synuclein (Sigma-Aldrich) and polyclonal rat sera against human 
recombinant TPPP/p25 [21] followed by Alexa 488 conjugated anti-mouse antibody 
and Alexa 546 conjugated anti-rat antibody  (Invitrogen). The samples were washed 
thrice with PBS after antibody incubation. Nuclei were counterstained with 4,6-
diamidino-2-phenylindole (DAPI). For samples containing -synuclein, Triton–X-100 
was changed to 30 µM digitonin, otherwise the protocol remained the same.  Images 
of fixed samples were acquired on a Leica DMLS microscope. Figure 4 was imaged 
on Zeiss LSM710 confocal microscope.  
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2.15 Immunoblotting 
The uptake of TPPP/p25 by HeLa/CHO10 cells was detected by immunoblotting as 
described previously [17] using a polyclonal rat serum against human recombinant 
TPPP/p25 [21]. The loading control was glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) detected by a monoclonal GAPDH antibody (Calbiochem). 
3. RESULTS AND DISCUSSION 
3.1 Structural characterization of the TPPP/p25 forms 
Previously we reported that TPPP/p25 is an intrinsically disordered protein with 
extended unstructured N- and C-terminal regions (45 and 44 aa) straddling a middle, 
flexible segment (130 aa) [11].  In order to get information whether the structural and 
functional properties of TPPP/p25 are altered by the removal of the terminal 
segments, N- or C-terminal truncated versions of TPPP/p25 as well as double 
truncated TPPP/p25 form were produced by recombinant technique (Fig. 1). 
The structural characteristics of these human recombinant TPPP/p25 forms were 
established by CD, FT-IR, fluorescence spectroscopy and limited proteolysis. As 
shown in Fig. 2A, the full length TPPP/p25 displayed a CD spectrum with a definitive 
minimum at 205 nm, characteristic for disordered proteins. Absence of either the N- 
or the C-terminus caused slight spectral alteration which became more pronounced in 
the case of the double truncated TPPP/p25: the position of the minimum shifted to a 
higher wavelength and the ratio of ellipticities measured at 222 nm and at the 
minimum increased (Fig. 2A).  
To study whether this change can be attributed to the appearance of the -sheet 
structure, FT-IR spectroscopy was carried out in the 1750-1500 cm
-1 
region which 
provides information on the Amide I-II bands [26-27]. We found that the FT-IR 
spectrum of the double truncated TPPP/p25 was not changed significantly as 
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compared to that of the full length protein (Fig. 2B). The main band of the Amide I 
region was at 1645 cm
-1
, which mainly corresponds to random conformation, 
however, alpha-helix (typically around 1650-1660 cm
-1
) and/or turns (1656-1671 cm
-
1
) structures could be involved. The slight shoulder at 1620 cm
-1
 present in the 
spectrum of the full length TPPP/p25 may indicate the occurrence of a not significant 
-sheet structure which is not visible in the case of the double truncated form. In 
addition, minimal difference could be detected in the Amide II band (around 1565 cm
-
1
). 
In a recent work we have established the presence of “molten globule” in the flexible 
middle segment of TPPP/p25 by fluorescence spectroscopy [28]. ANS fluorescence 
probe is appropriate to detect hydrophobic regions of proteins specifically if it is 
related to a molten globule state and not to globular or unfolded states [29-30]. As 
shown in Fig. 2C, the truncation of the unstructured tails of TPPP/p25 resulted in 
much less fluorescence intensity coupled with a smaller blue shift of the maximum of 
the emission spectrum. This finding could be indicative for the truncation-induced 
conformational change in the case of TPPP/p25.   
Finally, a limited proteolysis study was performed with the full length and the double 
truncated TPPP/p25 forms since it is a sensitive tool to detect alteration in the 
structural integrity of proteins. The protein forms were digested with chymotrypsin, 
and the digests were analysed by SDS-PAGE. Fig. 2D illustrates the results of the 
time-dependent proteolysis: the full length protein was fully degraded after 40 
minutes, while the double truncated TPPP/p25 displayed significantly less 
vulnerability towards the protease, even after 40 minutes two stable bands could be 
detected indicating the resistance of these two distinct partially digested forms against 
degradation. These data show that the truncation of both termini resulted in significant 
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structural alteration of the middle flexible segment, apparently it became more 
compact. Further investigations are needed for the identification of these stable 
structures. 
3.2 Interaction of tubulin with the distinct TPPP/p25 forms 
In order to determine whether the truncation-mediated changes in the structure of 
TPPP/p25 affect its physiologically relevant function, namely its interaction with 
tubulin, we investigated the tubulin binding, microtubule assembly promoting and 
microtubule bundling activities of the different TPPP/p25 forms.  
The tubulin binding potency of the TPPP/p25 forms was analyzed by CD 
spectroscopy as we previously demonstrated by far-UV CD that the association of 
TPPP/p25 with tubulin produced a characteristic difference spectrum due to the 
structural alterations within the heterologous complex (Fig. 3A) [13]. A similar set of 
experiments with the truncated forms showed that the lack of N- and/or C-terminus 
reduced this effect to different extents; the double truncation virtually diminished the 
formation of the difference spectrum (Fig. A.1 and Fig. 3A). Thus it could be 
concluded that the disordered termini are directly or indirectly involved in the hetero-
complex formation accompanied by CD spectral alteration.  
The functional consequences of the truncation of TPPP/p25 on its tubulin 
polymerization promoting activity were investigated by turbidity measurements. 
Typical time courses of turbidity induced by the different TPPP/p25 forms  revealed 
the distinct polymerization potency of the truncated forms as compared to the full 
length one (Fig. 3B). It can be unambiguously concluded that the double truncated 
form could not produce tubulin polymers with length larger than 350 nm causing 
turbidity. The tubulin polymerization potency of the N-terminal truncated and much 
more that of the C-terminal truncated form was reduced. These results demonstrate 
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that the disordered termini, even if in different extent, are involved in the tubulin 
polymerization activity of TPPP/p25.  
Previously we reported that the TPPP/p25-induced tubulin polymerization promoting 
activity is coupled with the extensive bundling of the microtubules [13]. To test the 
bundling potency of the truncated forms, two sets of experiments were performed.  
In one set of experiments the effects of the full length and truncated TPPP/p25 forms 
on the turbidity of paclitaxel-stabilized tubulin were tested. Fig. 3C shows that both 
the single and the double truncation of TPPP/p25 diminished its microtubule bundling 
activity suggesting that the disordered termini play significant role in the cross-linking 
of microtubules.   
In a second set of experiments, a pelleting experiment was performed in which the 
partition of the TPPP/p25 between the pellet (microtubules) and the supernatant 
(tubulin) fraction was investigated.  
As shown in Fig. 3D, both the TPPP/p25 forms and the tubulin were partitioned 
between the pellet and the supernatant fractions. While in the case of the full length 
TPPP/p25, the proteins were nearly equally partitioned between the pellet and the 
supernatant fractions, the amounts of both the tubulin and the truncated TPPP/p25 
forms were reduced in the pellet fraction indicating the decreased polymerization 
potency of the truncated TPPP/p25 forms in accordance with the turbidity data (Fig. 
3B). The reduced polymerization potency due to the truncation was the most 
pronounced for the double truncated TPPP/p25.  
3.3 Intracellular localization of the TPPP/p25 forms in HeLa cell 
As we revealed earlier TPPP/p25 co-localizes with the microtubule network in 
different cell lines expressing TPPP/p25 either exogenously (HeLa, CHO) or 
endogenously (CG-4), and the protein regulates the dynamics and organization of the 
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microtubule network via its microtubule bundling activity which enhances 
microtubule stability [16-17]. In order to obtain in vivo data for the role of the 
disordered terminal tails of TPPP/p25 in its microtubule-related function, HeLa cells 
were transiently transfected with the full length or the double truncated EGFP-
TPPP/p25 and the intracellular localizations of the proteins were visualized by 
confocal microscopy after immunostaining for -tubulin. Fig. 4 shows that while the 
full length TPPP/p25 tightly co-localized with the microtubule network in agreement 
with our earlier observations [16], the double truncated form distributed 
homogeneously within the cytoplasm. The finding that the double truncated 
TPPP/p25 cannot associate with the microtubule network underlines the role of the 
unstructured termini in the physiological function of TPPP/p25. 
3.4 Interaction of -synuclein with the distinct TPPP/p25 forms 
It has been revealed that TPPP/p25 interacts with -synuclein [22], and it is a 
potential inducer of -synuclein fibrillation [23]. In order to identify the role of the 
disordered termini of TPPP/p25 in its pathological interaction, the binding of the 
TPPP/p25 forms to -synuclein and their -synuclein aggregation promoting activity 
were investigated first in vitro. 
In an ELISA assay the affinities of the double truncated and the full length TPPP/p25 
forms to -synuclein were determined. The TPPP/p25 forms were immobilized on 
ELISA plates, then -synuclein was added at different concentrations. Complex 
formation was detected by a specific -synuclein antibody. -synuclein bound to both 
TPPP/p25 forms (Fig. 5A) revealing that the binding motif is localized within the 
middle segment as suggested by our previous Pepscan experiment [22]. The binding 
affinities of the full length and the double truncated TPPP/p25 forms to -synuclein 
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evaluated by curve fitting assuming simple hyperbolic saturation were found to be 
0.59 ± 0.07 and 0.81 ± 0.09 M, respectively.  
Thioflavin T fluorescence measurement is a suitable method to follow the formation 
of amyloid-type ( -sheet rich) aggregates of -synuclein [31] which likely occurs in 
the course of pathological inclusion formation as demonstrated earlier [23]. Fig. 5B 
shows that both the full length and the double truncated TPPP/p25 displayed similar 
-synuclein aggregation promoting potency, while auto-aggregation of -synuclein or 
the TPPP/p25 forms was not detected. The finding that the double truncated 
TPPP/p25 induced -synuclein aggregation in concert with the ELISA data 
corroborates that the disordered terminal tails of TPPP/p25 are probably not involved 
in the formation of the pathological heterocomplex. 
3.5 Colocalization of TPPP/p25 forms with -synuclein in CHO10 cells 
In order to test the role of the unstructured termini in the -synuclein aggregation 
promoting activity of TPPP/p25, an in vivo cell model was established.  
A CHO10 cell line that expresses full length TPPP/p25 ectopically following 
doxycyclin induction [17] was established as an appropriate system since these cells 
could take up -synuclein from the culture media (Fig. 6A). This finding is in 
agreement with a recent report that demonstrates the transcellular spread of secreted 
α-synuclein oligomers in human H4 neuroglioma cells by exosomal transmission [32]. 
Here we show that TPPP/p25 can also be taken up by both the CHO10 and the HeLa 
cell lines as demonstrated by Western-blot (Fig. A.2) and the cellular uptake of both 
the full length and the double truncated TPPP/p25 can be visualized by fluorescence 
microscopy (Fig. 6B and 6C) just as that of -synuclein (Fig. 6A). The intracellular 
appearance of -synuclein or the double truncated TPPP/p25, but not the full length 
TPPP/p25 resulted in the formation of aggregates in a few cases (Fig. 6A and C vs B).  
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The -synuclein aggregation promoting activity of the TPPP/p25 forms was 
characterized in CHO10 cells with and without the expression of the full length 
TPPP/p25.  As shown in Fig. 7, co-aggregation of -synuclein with either the full 
length or the double truncated TPPP/p25 forms can be visualized in non-induced 
CHO10 cells where all these proteins were taken up by the cells from the medium 
after their premixing (Fig. 7 lane 3 and 4, respectively). The added double truncated 
TPPP/p25 apparently displayed higher aggregation promoting activity as compared to 
the full length one, probably due to the fact that it is unable to bind to the microtubule 
network (cf. Fig. 4) therefore its free intracellular level is higher resulting in more 
pronounced -synuclein aggregation promoting activity. The expression of the full 
length TPPP/p25 after doxycyclin induction only slightly contributed to -synuclein 
aggregate formation (Fig. 7, lane 1 vs lane 3). The expressed full length TPPP/p25 
rather co-localized with the microtubule network than with -synuclein (Fig. 7 lane 1 
and 2, Fig. A.3) as its binding affinity to tubulin is higher than to -synuclein [22]. In 
contrast, when double truncated TPPP/p25 was added to the medium in addition to the 
TPPP/p25 expression, the aggregates increased in number and size (Fig. 7 lane 2 vs 
lane 1), which confirms the more pronounced -synuclein aggregation promoting 
potency of the double truncated TPPP/p25 and strengthens our suggestion that it is 
because of its higher free intracellular level due to its inability to bind to microtubules. 
Nevertheless, these findings provide evidence for the intracellular association of both 
TPPP/p25 forms with -synuclein and support that the disordered termini do not take 
part in the formation of pathological aggregates.  
The extracellular transmission of these disordered hallmark proteins seems to have 
pathological significance and may explain how the co-enrichment of -synuclein and 
TPPP/p25 could be evolved in the case of PD and Multiple System Atrophy in 
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neurons and oligodendroglia cells, respectively, though under physiological 
conditions these cells do not express these two proteins simultaneously. Indeed, the 
presence of both -synuclein and TPPP/p25 was detected in the cerebrospinal fluid of 
human patients previously [19, 33-34]. 
3.6 Validation of the tubulin and -synuclein binding motives of TPPP/p25 
To validate the binding motives within the C-terminus (44 aa) and the middle flexible 
segment (130 aa) of TPPP/p25 that are predominantly involved in its 
heteroassociation with tubulin and -synuclein, respectively, special ELISA 
experiments were performed with synthesized TPPP/p25 peptides.  
 For the identification of the tubulin binding motif of TPPP/p25, peptides were 
designed and synthesized according to data obtained with the truncated forms as 
compared to the full length TPPP/p25 and prediction based on the sequence homology 
between TPPP/p25 and the tubulin binding site of tau [35]: 
tubulin binding motif of tau:  
315
VYKPVDLSKVTSKCGSLGNIHHKPGGGQ
341
;  
C-terminal tail of TPPP/p25: 
163
VSRLTDTTKFT - - - GSHKERFDPSGKGK
187
.  
Accordingly, the following overlapping decapeptides were synthesized with a Cys 
residue that rendered possible their direct immobilization to an ELISA plate via their 
SH groups: 
 P1 C
163
VSRLTDTTKF
172
 
 P2 C
168
DTTKFTGSHK
177
 
 P3 C
173
TGSHKERFDP
182
 
 P4 C
178
ERFDPSGKGK
187
 
Tubulin at different concentrations was added to the immobilized peptides; the 
peptide-bound tubulin was quantified with a tubulin antibody as described in the 
Materials and Methods.  
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The P4 peptide (178-187 aa) bound to tubulin with comparable affinity as TPPP/p25 
(Kd = 0.135 ± 0.041 and 0.180 ± 0.030 M for TPPP/p25 and P4 peptide, 
respectively), while the three other peptides displayed lower affinity (Fig. 8). 
Accordingly, the 
178
ERFDPSGKGK
187
 segment of the C-terminal tail is the key 
binding motif on TPPP/p25 responsible for tubulin binding. Nevertheless, this issue 
does not exclude the involvement of other parts such as the N-terminal tail in the 
function of TPPP/p25 as noticed in the case of the turbidity measurements (cf. Fig. 3). 
To reinforce the localization of the -synuclein binding motif in a specific segment of 
the middle region of TPPP/p25 suggested by the Pepscan data, 
147
KAPIISGVTKAISSPTVSRL
166
 [22], ELISA experiments were performed with 
biotinylated decapeptides. The peptides were synthetized to cover the potential -
synuclein binding segment. The decapeptides with biotinylated tag rendered it 
possible to test the binding potency of the -synuclein directly to the peptides 
immobilized on a streptavidin-covered plate.  To test whether the biotinylation of the 
peptides at one of their termini affects the interactions, modification of one of the 
peptides at N- or C-terminus was alternatively performed as shown below:  
 BF180: C-biotinylated: Ac-
142
RLIEGKAPII
151
K-NH2 
      BF181: N-biotinylated: H-
142
RLIEGKAPII
151
 -NH2 
     BF182: C-biotinylated: Ac-
147
KAPIISGVTK
156
-NH2 
      BF183: C-biotinylated: Ac-
157
AISSPTVSRL
166
K -NH2 
There is no significant difference in the binding affinity of the -synuclein to the 
immobilized peptides as revealed by a specific -synuclein antibody (Fig. 9A). The 
apparent affinity constants (Kd) obtained by fitting the experimental points with a 
simple hyperbolic saturation curve were 2.91 ± 0.69, 3.60 ± 0.57, 4.15 ± 0.24 and 
4.01 ± 0.18 M for the BF180, BF181, BF182 and BF183 peptides, respectively; 
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which are significantly higher than that determined for the double truncated (0.81 ± 
0.09 M) and for the full length (0.59 ± 0.07 M) TPPP/p25 (cf. Fig. 5A). The -
synuclein binding is apparently independent of the nature of the decapeptides selected 
as well as the position of the biotinylation label. Consequently one can conclude that 
the binding is independent of the position of the biotinylation, but cannot exclude its 
role in the binding. 
Another, competitive ELISA experiment was carried out with the biotinylated 
peptides, however, they were premixed with -synuclein in solution then added to the 
full length or double truncated TPPP/p25 forms immobilized on ELISA plates.  The 
inhibitory effect of the peptides on the binding of -synuclein to TPPP/p25 forms was 
detected by a specific -synuclein antibody. In the experiment presented in Fig. 9B, 
-synuclein was added at constant concentration which corresponded roughly to the 
half saturation value (cf. Fig. 5A), and the peptides were preincubated with -
synuclein at 10 and 20 M concentrations. The results showed that i) there was a 
single peptide, BF182, which inhibited the heteroassociation of the -synuclein with 
TPPP/p25; ii) the extent of the inhibition was similar in the case of the full length and 
the double truncated protein; iii) the inhibitory effect of the BF182 was concentration-
dependent; iv) the BF180, BF181 and BF183 peptides were virtually ineffective 
concerning their inhibitory effects on the heteroassociation independently of the 
position of the biotinylation. These data seem to contradict the direct binding data 
where the -synuclein displayed similar affinity to each biotinylated TPPP/p25 
peptide (Kd ~ 4 M), in addition, this affinity was lower as determined for the full 
length/double truncated protein (Kd = 0.59 M / 0.81 M). A plausible way to 
interpret these ELISA data is that the disordered -synuclein may have another 
 - 22 - 
binding segment interacting with the biotinylated TPPP/p25 peptides, but the segment 
is out of the contact surface of the TPPP/p25- -synuclein pathological complex.  
The findings with the peptides and truncated TPPP/p25 forms suggest that the amino 
acids and/or short peptides within the middle segment of TPPP/p25 could generate a 
specific structure such as a foldamer, for the -synuclein binding to form the 
pathologically relevant heteroassociation leading to aggregation. 
4. CONCLUSIONS  
In conclusion, TPPP/p25 is a protein with a neomorphic moonlighting feature that is 
related to its disordered structure which permits multiple interactions with distinct 
proteins forming physiological or pathological complexes. In this paper the structural 
and functional features of the disordered N- and C-terminal tails of TPPP/p25 were 
characterized. Our data revealed the key role of the C-terminus and the fact that the 
N-terminus is also involved, even if to a much less extent, in its physiological 
function related to the modulation of the dynamics and organization of the 
microtubule network. In contrast, the -synuclein binding and aggregation promoting 
activity of TPPP/p25 is virtually not influenced by the truncation of the terminal tails. 
Experiments with designed and synthesized TPPP/p25 peptides rendered it possible to 
validate the binding motives for tubulin and -synuclein (Fig. 10). The ELISA 
experiments with decapeptides covering the potential tubulin and -synuclein binding 
segments localized these binding motives on the C-terminal tail 
(
178
ERFDPSGKGK
187
) and within the middle region (
147
KAPIISGVTK
156
) of 
TPPP/p25, respectively. The results obtained with the overlapping decapeptides may 
allow one to further reduce the binding motives to five-amino-acid segments which 
are substantial for the formation and maintenance of physiological and pathological 
heterocomplexes. The distinct localization of these binding motives in the disordered 
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TPPP/p25 assigns its neomorphic moonlighting functions and has innovative potential 
in the development of anti-synucleinopathy drugs.  
5. LIST OF ABBREVIATIONS USED 
1-anilino naphthalene-8-sulfonic acid, ANS; bovine serum albumin, BSA; circular 
dichroism, CD; 4,6-diamidino-2-phenylindole, DAPI; dithioerythritol, DTE; enzyme-
linked immunosorbent assay, ELISA; Fourier transformed infrared spectroscopy, FT-
IR; glyceraldehyde 3-phosphate dehydrogenase, GAPDH; Parkinson’s disease, PD; 
phosphate buffered saline,  PBS; polymerase chain reaction,  PCR; sodium dodecyl 
sulfate polyacrylamide gel electrophoresis, SDS-PAGE; solid phase peptide synthesis, 
SPPS; Tubulin Polymerization Promoting Protein, TPPP/p25. 
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9. FIGURE LEGENDS 
Figure 1 - Scheme of the different TPPP/p25 forms (A) with the SDS/PAGE 
images (B). 
(B) MM: molecular weight marker, lane 1: TPPP/p25, lane 2: N-terminal truncated 
TPPP/p25, lane 3: C-terminal truncated TPPP/p25, lane 4: double truncated 
TPPP/p25. 
Figure 2  - Structural characterization of the different TPPP/p25 forms. 
 (A) Normalized far-UV CD spectra. TPPP/p25 (bold line), N-terminal truncated 
TPPP/p25 (solid line), C-terminal truncated TPPP/p25 (dashed line), double truncated 
TPPP/p25 (dotted line). The standard error of the determinations (SEM) was ± 10% 
(n=3). (B) FT-IR spectrum of the full length (bold line) and the double truncated 
(dotted line) TPPP/p25. (C) ANS fluorescence spectroscopy. Emission spectra of free 
ANS (dash-dot-dotted line), ANS with full length (bold line) and double truncated 
(dotted line) TPPP/p25. The concentration of protein and ANS was 50 M and 2.5 
M, respectively. The standard error of the determinations (SEM) was ± 10% (n=3-
5). (D) Time-dependent limited proteolysis of the full length and the double truncated 
TPPP/p25 with chymotrypsin terminated at 0, 10, 20 and 40 minutes and analyzed by 
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SDS-PAGE. A representative experiment is presented. The standard error of the 
determinations (SEM) was ± 10% (n=3-4). 
Figure 3  - Interaction of tubulin with the distinct TPPP/p25 forms. 
(A) Difference CD spectra of TPPP/p25 forms and tubulin. Difference ellipticity was 
calculated by subtracting the ellipticities of tubulin and the TPPP/p25 forms from that 
measured with their mixtures. The concentration of tubulin was 1 M, while that of 
the TPPP/p25 forms was 4 M.  (B) The tubulin polymerization promoting potency of 
the TPPP/p25 forms followed by turbidimetry. The polymerization of 7 M tubulin to 
microtubules was induced by the addition of 3 M of each TPPP/p25 form. (C) The 
microtubule bundling potency of the TPPP/p25 forms as determined by a 
turbidimetric assay. Tubulin (10 M) polymerization was induced by paclitaxel (20 
M), and TPPP/p25 (3 M) forms were added subsequently. (D) Pelleting 
experiment. 5 M tubulin was incubated with 10 M of each TPPP/p25 form in 
polymerization buffer. After centrifugation, the pellet/microtubule (P) and the 
supernatant/tubulin (S) fractions were separated and analysed by SDS-PAGE on a 
Tris-Tricine two-layer gel. TPPP/p25 (bold line), N-terminal truncated TPPP/p25 
(solid line), C-terminal truncated TPPP/p25 (dashed line), double truncated TPPP/p25 
(dotted line) (A-C). The standard error of the determinations (SEM) was ± 10% (n=3-
5).  
Figure 4  - Localization of the TPPP/p25 forms in HeLa cells. 
Transiently transfected cells with pEGFP-TPPP/p25 (A-C, green) or pEGFP-double 
truncated TPPP/p25  (D- -tubulin antibody (red) 
and visualized by confocal microscopy. Note the co-localization of TPPP/p25 along 
the microtubule network (C) in contrast to the homogenous distribution of the double 
truncated TPPP/p25 within the cytoplasm (F). Nuclei were counterstained with DAPI 
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(blue). Scale bar: 10 m. 
Figure 5  - The interaction of the full length and the double truncated TPPP/p25 
forms with -synuclein. 
(A) ELISA experiment. The plate was coated with TPPP/p25 (●, , , ) or the 
double truncated form of the protein (○, , , ), then -synuclein was added at 
different concentrations. The different symbols indicate independent experiments. The 
normalized ELISA data were calculated as the absorbance at a given -synuclein 
concentration divided by the absorbance at saturation. The binding affinities of the 
full length (bold line) and the double truncated (dashed line) TPPP/p25 forms to -
synuclein were evaluated by curve fitting assuming simple hyperbolic saturation. (B) 
Aggregation of -synuclein induced by the different TPPP/p25 forms followed by 
thioflavin T fluorescence emission at 480 nm. 150 M -synuclein was incubated in 
the absence and presence of 10 M TPPP/p25 or double truncated TPPP/p25 in PBS 
buffer for 4 days at 37 °C, and the samples were analyzed by Thioflavin T 
fluorescence. TPPP/p25 or the double truncated TPPP/p25 alone was incubated under 
the same conditions. The spectrum of Thioflavin T was subtracted from that of the 
sample in each case. Error bars represent the standard error of the determinations 
(SEM) (n=3). * Significant difference between -synuclein and -synuclein 
incubated with the full length or the double truncated TPPP/p25 (according to the 
Student’s t-test, p<0.05). 
Figure 6  - Cellular uptake of -synuclein or the TPPP/p25 forms as detected by 
immunofluorescence microscopy. 
Non-induced CHO10 cells took up human recombinant -synuclein (A, red) or the 
TPPP/p25 forms (B and C, red) from the cell culture media as visualized by 
immunostaining for -synuclein or TPPP/p25, respectively. The TPPP/p25 forms 
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were stained by the same antibody [21]. Nuclei were counterstained with DAPI 
(blue). Scale bar:  m. 
Figure 7  - Intracellular localization of the TPPP/p25 forms and -synuclein in 
CHO10 cells as detected by immunofluorescence microscopy. 
CHO10 cells with (lane 1-2) and without (lane 3-4) full length TPPP/p25 expression 
took up full length (lane 1 and 3, red) or double truncated (lane 2 and 4, red) 
TPPP/p25 and -synuclein (lane 1-4, green) from the medium after premixing as 
visualized by immunostaining for TPPP/p25 and -synuclein, respectively. Note that 
either the expressed (lane 1 and 2) or the added full length TPPP/p25 (arrowhead at 
lane 3) was rather colocalized with the microtubule network than with -synuclein. 
The double truncated TPPP/p25 and -synuclein were co-enriched in cytoplasmic 
aggregates (lane 2 and 4) which were more pronounced both in number and size than 
the aggregates induced by full length TPPP/p25 expression (lane 1) or uptake (lane 3). 
Nuclei were counterstained with DAPI (blue). Scale bar: m. 
Figure 8  - The interaction of TPPP/p25 and the decapeptides with tubulin 
followed by ELISA. 
The plate was coated with the P1-P4 peptides or TPPP/p25 via their SH groups, then 
it was incubated with tubulin at different concentrations. TPPP/p25 (●), P1 (Δ), P2 
(○), P3 ( ) and P4 (). 
Figure 9  - The interaction of decapeptides with -synuclein followed by ELISA 
and the effect of biotinylated peptides on TPPP/p25 – -synuclein interaction. 
(A) The plate was coated with streptavidin, then the biotinylated peptides were added 
to the plate. Next it was incubated with -synuclein at different concentrations. 
BF180 (●, solid line), BF181 (○, dashed line), BF182 (, dotted line) and BF183 (Δ, 
dash-dot-dotted line). (B) The plate was coated with the full length (white column) or 
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the double truncated (black column) TPPP/p25 form. Then 500 nM -synuclein 
preincubated with the biotinylated peptides BF180-183 (10 and 20 M) was added to 
the plate. The interaction was detected by an -synuclein antibody. Error bars 
represent the standard error of the determinations (SEM) (n=3). 
Figure 10  - Scheme of  the tubulin and -synuclein binding motives of TPPP/p25 
as validated by different TPPP/p25  peptides. 
Localization of the different TPPP/p25 peptides in the sequence of TPPP/p25 and the 
amino acid sequence of the potential binding site of tubulin (green) and -synuclein 
(blue) are shown in red frames. 
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Figure 2. 
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Figure 3. 
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Figure 4. 
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Figure 5. 
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Figure 6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 39 - 
Figure 7. 
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Figure 8. 
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Figure 9. 
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Figure 10. 
 
 
 
 
 
 
